arrow
M

Mark Frydenberg

monash university
H指数:63
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial

一种适用于符合主动监测条件的低风险前列腺癌男性及其伴侣的在线治疗决策辅助工具可增加主动监测的接受度:Navigate随机对照试验

2025-04-120
OAAI
Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment

1级前列腺癌主动监测的长期结果以及使用MRI对过度治疗的影响

2025-04-010
OAAI
A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol

人工智能驱动的生物标志物的多中心实施试验,以告知接受前列腺放疗的男性雄激素剥夺治疗的共同决定: stute方案

2025-02-130
OAAI
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial

中高危前列腺癌男性68Ga-PSMA-11正电子发射断层扫描/计算机断层扫描的基线淋巴结状态是治疗失败的预后因素: proPSMA试验的随访

2024-11-290
OAAI
Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care

导航治疗决策辅助工具的成本-效用分析——用于与常规护理相比的男性前列腺癌患者及其伴侣研究

2024-08-010
PRE
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer
2024-08-018
PRE
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry

主动监测前列腺癌是否已变得更安全?全球临床登记研究的经验教训

2024-07-010
OAAI
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial

来自TRANSFORM II期试验的分割立体定向放射治疗寡转移前列腺癌的五年结果

2024-06-193
PRE
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [ 68 Ga]Ga-PSMA-11 Positron Emission Tomography/ Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer

PRIMARY2的临床试验方案: 一项多中心,3期,随机对照试验,研究 [68 Ga]Ga-PSMA-11正电子发射断层扫描/计算机断层扫描对男性阴性或模棱两可的多参数磁共振成像诊断临床意义的前列腺癌的附加诊断价值

2024-06-017
OA
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database
2023-11-307
OA
Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
2023-10-010
OAAI
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy

结合临床参数、多参数磁共振成像和前列腺特异性膜抗原正电子发射断层扫描的新型风险计算器,用于经会阴前列腺活检前的前列腺癌风险分层

2023-07-018
OAAI
Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi- institutional Study
2023-07-0110
OAAI
Can 68Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

68Ga-PSMA正电子发射断层扫描和多参数MRI能否指导前列腺癌根治术后生化复发的治疗?

2023-05-164
OA